Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13.
The antibody genetics of multiple sclerosis: comparing next-generation sequencing to sanger sequencing.
Neuropathology of multiple system atrophy: New thoughts about pathogenesis.
Spatial modeling of multiple sclerosis for disease subtype prediction.
Conditioned Medium from the Stem Cells of Human Exfoliated Deciduous Teeth Ameliorates Experimental Autoimmune Encephalomyelitis.
Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica.
RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?
Antibodies as Mediators of Brain Pathology.
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.
Evaluation of locomotor function and microscopic structure of the spinal cord in a mouse model of experimental autoimmune encephalomyelitis following treatment with syngeneic mesenchymal stem cells.
Multiple sclerosis: Teriflunomide shows efficacy as an add-on therapy to IFN-β in patients with multiple sclerosis.
Characteristics of flow through the internal jugular veins at cervical C2/C3 and C5/C6 levels for multiple sclerosis patients using MR phase contrast imaging.
Multiple sclerosis guideline production takes off.
[Two new oral disease modifying therapies in relapsing remitting multiple sclerosis].
MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene.
Osmotic demyelination syndrome in Intensive Care Unit.
Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel.
Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis.
Study of type a and B behavior patterns in patients with multiple sclerosis in an Iranian population.
Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.
Certified occupational therapy assistants.
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Multiple sclerosis: The elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
The effect of plasma exchange on serum anti-JC virus antibodies.
Pages
« first
‹ previous
…
478
479
480
481
482
483
484
485
486
…
next ›
last »